| Literature DB >> 25853515 |
Kimberly Loesch1, Stacy Galaviz1, Zaher Hamoui2, Ryan Clanton2, Gamal Akabani3, Michael Deveau4, Michael DeJesus5, Thomas Ioerger5, James C Sacchettini1, Deeann Wallis1.
Abstract
Elucidating the genetic determinants of radiation response is crucial to optimizing and individualizing radiotherapy for cancer patients. In order to identify genes that are involved in enhanced sensitivity or resistance to radiation, a library of stable mutant murine embryonic stem cells (ESCs), each with a defined mutation, was screened for cell viability and gene expression in response to radiation exposure. We focused on a cancer-relevant subset of over 500 mutant ESC lines. We identified 13 genes; 7 genes that have been previously implicated in radiation response and 6 other genes that have never been implicated in radiation response. After screening, proteomic analysis showed enrichment for genes involved in cellular component disassembly (e.g. Dstn and Pex14) and regulation of growth (e.g. Adnp2, Epc1, and Ing4). Overall, the best targets with the highest potential for sensitizing cancer cells to radiation were Dstn and Map2k6, and the best targets for enhancing resistance to radiation were Iqgap and Vcan. Hence, we provide compelling evidence that screening mutant ESCs is a powerful approach to identify genes that alter radiation response. Ultimately, this knowledge can be used to define genetic variants or therapeutic targets that will enhance clinical therapy.Entities:
Mesh:
Year: 2015 PMID: 25853515 PMCID: PMC4390347 DOI: 10.1371/journal.pone.0120534
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Cytotoxicity assay performance.
Estimate of Dead cell relative light units (RLU), Live cell RLU, and % Viability for all clones at 0-Gy, 0.5-Gy and 4-Gy irradiation. While dead cell RLUs do not show statistically significant changes, changes in live cell RLUs and % Viability at 4-Gy are statistically significant indicating that as a whole, clones show fewer live cells and decreased viability at 4-Gy, presumably due to cell cycle arrest and decreased cell division.
Genes associated with significant changes in viability.
| Gene | Change % Viability | Z-Score | p-value | ||
|---|---|---|---|---|---|
|
|
| Prdx3 | -30.89% | -4.41953 | 9.89E-06 |
| Bcap31 | -30.51% | -4.36329 | 1.28E-05 | ||
| Bach1 | -22.49% | -3.15661 | 0.001596 | ||
| Nrf1 | -22.37% | -3.13909 | 0.001695 | ||
| Vamp12 | -22.07% | -3.09443 | 0.001972 | ||
|
|
| Mcm2 | 25.78% | 4.100149 | 4.13E-05 |
| Cradd | 24.46% | 3.901591 | 9.56E-05 | ||
| Rbbp5 | 22.74% | 3.643607 | 0.000269 | ||
| Lims1 | 22.58% | 3.619399 | 0.000295 | ||
| Ctnna1 | 19.96% | 3.224992 | 0.00126 | ||
| Arl6ip5 | 19.87% | 3.212631 | 0.001315 | ||
| Dpagt1 | 19.55% | 3.164071 | 0.001556 | ||
| Rfx2 | 19.28% | 3.123158 | 0.001789 | ||
| Thrap3 | 18.98% | 3.078622 | 0.00208 | ||
| Casc3 | 18.37% | 2.98651 | 0.002822 | ||
| Ttl | 18.36% | 2.985033 | 0.002835 | ||
| Nrip1 | 17.72% | 2.88807 | 0.003876 | ||
| Mll3 | 17.69% | 2.883578 | 0.003932 | ||
| Psmb10 | 16.18% | 2.65656 | 0.007894 | ||
| Topors | 15.87% | 2.611167 | 0.009023 | ||
| Exo1 | 15.68% | 2.581592 | 0.009835 | ||
|
| Cdc25c | 39.77% | 5.313806 | 1.07E-07 | |
| Rab8a | 36.36% | 4.887382 | 1.02E-06 | ||
| Bclaf1 | 29.79% | 4.065455 | 4.79E-05 | ||
| Bcl7a | 23.51% | 3.280737 | 0.001035 | ||
| Kif22 | 19.35% | 2.760707 | 0.005768 | ||
| Cux1 | 19.16% | 2.736151 | 0.006216 | ||
| Scpep1 | 17.91% | 2.58025 | 0.009873 |
Genes associated with significant changes in gene expression.
| Gene | Log Ratio | Z-Score | p-value | ||
|---|---|---|---|---|---|
|
|
| Brcc3 | -1.77153 | -12.4129 | 0 |
| Grb7 | -0.62621 | -4.24135 | 2.22E-05 | ||
| Nap1l4 | -0.51406 | -3.44121 | 0.000579 | ||
| Cep68 | -0.51189 | -3.42576 | 0.000613 | ||
| Anapc7 | -0.50525 | -3.37836 | 0.000729 | ||
| Rfx2 | -0.45217 | -2.99962 | 0.002703 | ||
| Rhbdd3 | -0.40548 | -2.66652 | 0.007664 | ||
|
| Brcc3 | -1.85002 | -9.34039 | 0 | |
| Ing4 | -0.92325 | -4.48835 | 7.18E-06 | ||
| Epc1 | -0.89975 | -4.36531 | 1.27E-05 | ||
| Mtap4 | -0.89935 | -4.3632 | 1.28E-05 | ||
| Atp2b1 | -0.63371 | -2.97248 | 0.002954 | ||
| Adnp2 | -0.60024 | -2.79726 | 0.005154 | ||
| Diablo | -0.59001 | -2.74367 | 0.006076 | ||
|
|
| Serinc3 | 1.180251 | 6.524403 | 6.83E-11 |
| Pex14 | 0.739167 | 4.21514 | 2.5E-05 | ||
| Dstn | 0.468382 | 2.797459 | 0.005151 | ||
|
| Dstn | 0.441173 | 3.374142 | 0.00074 | |
| Pex14 | 0.383902 | 2.965529 | 0.003022 | ||
| Ptbp2 | 0.368237 | 2.853763 | 0.00432 | ||
| Prdx3 | 0.357476 | 2.776985 | 0.005487 | ||
| Ccnb1 | 0.351157 | 2.731898 | 0.006297 | ||
| Tnfaip8 | 0.345919 | 2.69453 | 0.007049 |
Evaluation of hits for GO enrichment.
| Phenotype | GO number | GO term | Genes | Total in population | Q-value |
|---|---|---|---|---|---|
| Increased Viability | GO:0044431 | Golgi apparatus part | Cux1, Rab8a | 8 | 0.0101 |
| Increased Viability | GO:0048193 | Golgi vesicle transport | Cux1, Rab8a | 8 | 0.0325 |
| Decreased Viability | GO:0007005 | mitochondrion organization | Nrf1 and Prdx3 | 6 | 0.0021 |
| Increased Expression | GO:0022411 | cellular component disassembly | Dstn, Pex14 | 18 | 0.0053 |
| Increased Expression | GO:0009607 | response to biotic stimulus | Prdx3, Tnfaip8 | 11 | 0.0084 |
| Increased Expression | GO:0043154 | negative regulation of cysteine-type endopeptidase activity involved in apoptotic process | Prdx3, Tnfaip8 | 5 | 0.0084 |
| Decreased Expression | GO:0000123 | histone acetyltransferase complex | Epc1, Ing4 | 4 | 0.0081 |
| Decreased Expression | GO:0005887 | integral component of plasma membrane | Atp2b1, Diablo | 6 | 0.0184 |
| Decreased Expression | GO:0040008 | regulation of growth | Adnp2, Epc1, Ing4 | 22 | 0.02 |
| Decreased Expression | GO:0000152 | nuclear ubiquitin ligase complex | Anapc7, Brcc3 | 7 | 0.0208 |
Selected radiation response genes.
| 0.5 Gy | 4 Gy | ||||||
|---|---|---|---|---|---|---|---|
| Symbol | Name | Function | Delta % Viability | B-Gal Fold Change | Delta % Viability | B-Gal Fold Change | Reason Selected |
| Iqgap1 | IQ motif containing GTPase activating protein 1 | IQGAP may regulate cell morphology; C-terminal domain of IQGAP inhibited the GTPase activity of cdc42 | 7.67 | -1.48 | -2.19 | -1.58 | Increased Viability |
| Dpagt1 | Dolichol phosphate GlcNAc-1-phosphate transferase | GlcNAc-1-P transferase, target of Wnt/beta-catenin signaling pathway | 19.55 | -2.01 | 7.06 | -1.78 | Increased Viability |
| Bclaf1 | BCL2-associated transcription factor 1 | induction of apoptosis, negative regulation of transcription, DNA-dependent, a transcriptional repressor that interacts with BCL2-related proteins | 6.93 | -1.29 | 29.79 | -1.70 | Increased Viability |
| Cdc25c | cell division cycle 25C | cell cycle, cell division, phosphoprotein phosphatase activity | 9.40 | 1.19 | 39.77 | -1.39 | Increased Viability |
| Kif22 | kinesin family member 22 | DNA repair, microtubule-based movement; may play a role in regulating the movement of chromosomes along microtubules during mitosis | 14.46 | -1.02 | 19.35 | -1.60 | Increased Viability |
| Bach1 | BTB and CNC homology 1 | negative regulation of transcription from RNA polymerase II promoter | -22.49 | 1.35 | -21.38 | 1.34 | Decreased Viability |
| Dynlrb1 | dynein light chain roadblock-type 1 | microtubule-based movement, transport | -15.96 | -1.13 | -20.32 | 1.57 | Decreased Viability |
| Map2k6 | mitogen-activated protein kinase kinase 6 | Serine/threonine-protein kinase | 3.51 | 1.69 | -10.32 | 2.18 | Decreased Viability |
| Wapal | wings apart-like homolog (Drosophila) | cell cycle, cell division; oncogene, malfunction of the WAPL pathway may activate an S phase checkpoint or other apoptotic pathway leading to cell death | 5.47 | -1.16 | -12.55 | 1.13 | Decreased viability |
| Hnrnpa3 | heterogeneous nuclear ribonucleoprotein A3 | mRNA transport | -15.45 | 1.25 | -18.12 | 1.16 | Decreased viability |
| Vcan | Versican | A proteoglycan, interferes with CD44/ErbB-dependant signaling; specifically interacts with hyaluronan | -2.98 | 1.21 | -3.92 | 2.30 | Increased Expression |
| Dstn | Destrin | actin depolymerizing factor | 6.00 | 2.76 | -6.00 | 2.94 | Increased Expression |
| Ing4 | Inhibitor of growth familiy member 4 | tumor suppressor, apoptotic process, cell cycle; regulates brain tumour angiogenesis through transcriptional repression of NF-kappaB-responsive genes | -1.00 | -1.10 | -8.00 | -8.38 | Decreased Expression |
| Rbpms | RNA binding protein with multiple splicing | RNA-binding protein: marker for retinal ganglion cells; positive regulation of pathway-restricted SMAD protein phosphorylation | 12.39 | -1.52 | -0.38 | -2.31 | Decreased Expression |
| Gspt1 | G1 to S phase transition 1 | involved in translation termination | -5.57 | -1.48 | 9.61 | -3.61 | Increased Viability; Decreased Expression |
| Cux1 | cut-like homeobox 1 | intra-Golgi vesicle-mediated transport | 2.12 | 1.08 | 19.16 | -2.46 | Increased Viability; Decreased Expression |
| Klf8 | Kruppel-like factor 8 | promotes tumor invasion | 5.29 | 1.00 | 13.34 | -3.08 | Increased Viability; Decreased Expression |
| Atp2b1 | ATPase, Ca++ transporting, plasma membrane 1 | ATP binding, hydrolase activity, Calcium ion transport | 13.90 | -1.39 | 14.00 | -4.30 | Increased Viability; Decreased Expression |
Fig 2Validation assays.
(A) Change in % viability over time for selected clones. (B) Change in gene expression over time for selected clones. (C) Change in % viability due to radiation dose for selected clones. (D) Change in gene expression due to radiation dose for selected clones. Error bars indicate SEM.
Fig 3Cell growth as a function of time for wild type (WT) and (A) Dpagt1-mutant ESCs, (B) Klf8-mutant ESCs, (C) Dstn-mutant ESCs, (D) Iqgap1-mutant ESCs, (E) Map2k6-mutant ESCs, (F) Vcan-mutant ESCs, (G) Rbpms-mutant ESCs.
Cells were irradiated with a dose of 2-Gy just before incubation using x-rays. Error bars indicate SEM.